Event-Driven Stocks

Verona Pharma plc

VRNA

Healthcare · Pharmaceutical Preparations · X0 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 3 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue$42.3M$0$458,000$40.0M$0—
Operating income−$154.6M−$67.6M−$75.8M−$73.3M−$74.3M−$52.4M
Net income−$173.4M−$54.4M−$68.7M−$55.6M−$65.1M−$40.6M
Total assets$474.2M$308.1M$259.5M$186.6M$204.2M$56.2M
Total liabilities$269.7M$58.8M$29.0M$38.6M$19.4M$13.5M
Equity$204.6M$249.3M$230.5M$148.0M$184.9M$42.7M
EPS (diluted)$-0.27$-0.09$-0.13$-0.12——
Shares out.646.5M631.9M482.9M463.5M463.3M105.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
−365.7%
Net margin
−410.2%
Return on equity
−84.8%
Return on assets
−36.6%
Return on capital (ROCE)
−35.8%
Liabilities / assets
56.9%
Debt / equity
1.32×
Book value / share
$0.32
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
0.42distress
Accruals / assets
−10.8%clean
Piotroski F-Score
2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
44
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 severe● 3 warning● 1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Sep 30, 20252.1M1.2+2.5%
Sep 15, 20252.0M1.5+0.8%
Aug 29, 20252.0M1.6-3.5%
Aug 15, 20252.1M1.4-15.8%
Jul 31, 20252.5M1.0-39.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.